NCT05158842 (Adult-bCPAP) is a NA clinical trial of Adult bubble CPAP oxygen therapy device in Severe Pneumonia, sponsored by International Centre for Diarrhoeal Disease Research, Bangladesh.

Who is sponsoring NCT05158842?

NCT05158842 is sponsored by International Centre for Diarrhoeal Disease Research, Bangladesh.

What drugs are being tested in NCT05158842?

Interventions in NCT05158842: Adult bubble CPAP oxygen therapy device.

What condition does NCT05158842 study?

NCT05158842 studies Severe Pneumonia, Acute Respiratory Distress Syndrome, Covid19.

Is NCT05158842 still recruiting?

NCT05158842 is currently completed. Last updated 25 August 2022.

Last reviewed 2022-08-25 · How we verify

NCT05158842: Adult-bCPAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of COVID-19 Positive/Negative Bangladeshi Adults With Severe Respiratory Complaints by a Locally Made bCPAP: Feasibility Study

Completed NA Last updated 25 August 2022

What this trial tests

NA trial testing Adult bubble CPAP oxygen therapy device in Severe Pneumonia in 20 participants. Completed in 17 February 2022.

Timeline

8 October 2021

Primary endpoint
17 February 2022

17 February 2022

Quick facts

Lead sponsor	International Centre for Diarrhoeal Disease Research, Bangladesh
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	20
Start date	8 October 2021
Primary completion	17 February 2022
Estimated completion	17 February 2022
Sites	2 locations across Bangladesh

Drugs / interventions tested

Adult bubble CPAP oxygen therapy device

Conditions studied

Severe Pneumonia — all drugs for Severe Pneumonia →
Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
Covid19 — all drugs for Covid19 →

Sponsor

International Centre for Diarrhoeal Disease Research, Bangladesh — full company profile →

Who can join

Adults 18 to 64, any sex, with Severe Pneumonia or Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Low and middle-income countries (LMICs) urgently need cost-effective adaptive technologies to provide CPAP. The lead investigator has designed a device that has already been approved by the Directorate General of Drug Administration (DGDA), Government of the People's Republic of Bangladesh. The design of the nasal seal was comfortable and well tolerated by all the participants. Patients were told about some mild discomfort at higher delivered pressures (14 or 15 cm PEEP), consistent with pressurised nasal delivery by similar devices. The safety phase has been initiated since 1st November 2020 and ended in April 2021. One patient withdrew from the study but none of them developed any adverse events. The feasibility phase started at the end of September 2021. Objectives: 1. To evaluate the barriers and operational challenges related to the introduction of adult bubble CPAP oxygen therapy 2. To evaluate the acceptability of introducing adult bubble CPAP in tertiary level hospitals of Bangladesh

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Severe Pneumonia

Currently open trials in the same condition.

NCT07461714 — AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia · active not recruiting
NCT06538441 — Dynamic Pattern of Etiology, Immunoinflammatory Factors and Their Association With Prognosis of Severe Pneumonia · active not recruiting
NCT06514781 — The Application of Different Sedation Protocols in ICU Patients With Severe Pneumonia · recruiting
NCT06114784 — Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study · recruiting
NCT06516601 — Fulminant Severe CAP - an Observational Study · recruiting

Other International Centre for Diarrhoeal Disease Research, Bangladesh trials

Trials by the same sponsor.

NCT07537686 — Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunc · Phase 2 · not yet recruiting
NCT07345208 — Safety and Immunogenicity of ID vs IM Rabies Vaccine · Phase 2, PHASE3 · not yet recruiting
NCT07045493 — Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh · Phase 2 · enrolling by invitation
NCT06757283 — ZyVac-TCV Bangladesh Study · Phase 3 · not yet recruiting
NCT06815835 — Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05158842 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by International Centre for Diarrhoeal Disease Research, Bangladesh
Last refreshed: 25 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05158842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing